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ABSTRACT
Four decades of preclinical research demonstrating survival, functional integration, and behavioral
effects of transplanted stem cells in experimental stroke models have provided ample scientiﬁc basis
for initiating limited clinical trials of stem cell therapy in stroke patients. Although safety of the
grafted cells has been overwhelmingly documented, efﬁcacy has not been forthcoming. Two recently
concluded stroke clinical trials on mesenchymal stem cells (MSCs) highlight the importance of strict
adherence to the basic science ﬁndings of optimal transplant regimen of cell dose, timing, and route
of delivery in enhancing the functional outcomes of cell therapy. Echoing the Stem Cell Therapeutics
as an Emerging Paradigm for Stroke and Stroke Treatment Academic Industry Roundtable call for an
NIH-guided collaborative consortium of multiple laboratories in testing the safety and efﬁcacy of
stem cells and their derivatives, not just as stand-alone but preferably in combination with approved
thrombolytic or thrombectomy, may further increase the likelihood of successful fruition of translating stem cell therapy for stroke clinical application. The laboratory and clinical experience with MSC
therapy for stroke may guide the future translational research on stem cell-based regenerative medicine in neurological disorders. STEM CELLS TRANSLATIONAL MEDICINE 2019;8:983–988

SIGNIFICANCE STATEMENT
Almost 4 decades of laboratory research have shown safety and efﬁcacy of stem cells in stroke
animals. Yet, this cell-based regenerative medicine remains designated as “experimental” in
the clinic. Equally disappointing, two recently concluded clinical trials indicated stem cells are
safe but not effective in stroke patients. These failed clinical trials may be due to a loss in translation of optimal laboratory stem cell transplantation protocols to clinical trial designs. A concerted
effort between basic scientists and clinicians, with NIH and Food and Drug Administration guidance, is key to realizing the safe and effective translation of stem cell therapy for stroke.

STEM CELL THERAPY FOR STROKE HAS REACHED
CLINICAL TRIALS. THE LONG WAIT IS OVER! OR
IS THE WAIT STILL ON?
In the late 1980s, Sharp and colleagues ushered
one of the pioneering laboratory investigations in
cell therapy for stroke, demonstrating the survival
of rat fetal neocortical grafts in ischemic adult rat
cortex [1, 2]. Subsequent studies showed that these
grafted fetal cells integrated with the ischemic
brain received afferent ﬁbers and vascularization
from the host intact tissue [3, 4] and responded to
contralateral sensory stimulation with increased
metabolic activity [5]. Equally promising are the
observations that stroke animals transplanted
with fetal striatal cells into the ischemic striatum
displayed some improvements in a simple cognitive task of passive avoidance [6], as well as in a
more complex water maze learning test [7].

Over the next 4 decades of preclinical research,
additional evidence of graft survival, migration,
differentiation, and functional integration in the
ischemic brain, modest anatomical reconstruction, and remodeling of brain circuitry, neurochemical, physiological, and behavioral recovery
have been documented [2, 8]. Several mechanisms have also been postulated to mediate the
therapeutic effects of cell transplants in stroke;
although initially designed as a cell replacement
for dead or ischemic cells, the current view puts
robust by-stander effects of the grafted cells to
secrete therapeutic substances [9–12]. The initial studies on human neuroteratocarcinoma cells
were to convert these cells into postmitotic
neuron-like cells [13]. Subsequent studies on
embryonic stem cells [14], genetically engineered
mesenchymal stem cells (MSCs; Sanbio, Mountain
View, CA) [15], and fetal-derived stem cells (by
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Primarily because of the long-track record of solid safety
proﬁle, the bone marrow has emerged as the widely used adult
tissue stem cell source [26, 28–32]. Bone marrow-derived cell
populations as well as engineered stem/progenitor cells have
been characterized, including but not limited to MSCs, mononuclear cells (MNCs), endothelial progenitor cells, SB623, multipotent
adult progenitor cells (MAPCs), and multilineage-differentiating
stress-enduring cells (Muse) [33–37]. These bone marrow-derived
stem cells have been widely examined in preclinical stroke models,
revealing the cells’ ability to display multipotent cell properties
in vitro [38–43] and to reduce behavioral and histological deﬁcits after transplantation in vivo [44], providing solid basis for
clinical trials. Autologous bone marrow MSCs when intravenously
transplanted in patients at 4 weeks after stroke onset displayed no
adverse effects and even improved neurological outcomes, but
such efﬁcacy declined by 12 months post-transplantation [45]. An
open-labeled trial of autologous transplantation of bone marrow
MNCs intravenously delivered in patients within 24–72 hours poststroke was also safe and exerted better functional recovery that
lasted for over 6 month post-transplantation [46]. However, a subsequent phase II, multicenter, parallel group, randomized, and
blinded trial demonstrated that autologous bone marrow MNCs
intravenously delivered at median of 18.5 days after stroke onset
was again safe but did not result in functional improvement [47].
Interestingly, another open-labeled trial employing an intra-arterial
deliver of a subset of CD34+ bone marrow MNCs within 7 days of
stroke onset was also shown to be safe with improved functional
outcomes during the 6-month post-transplantation period [48].
More recent clinical trials have reported mixed outcomes, in that
while overwhelmingly safe, demonstrating the efﬁcacy of stem cell
therapy for stroke has failed in both the intravenous transplantation of MAPCs in acute stroke patients [49] and the intracerebral
transplantation of SB623 in chronic stroke patients [50–52].
Based on these interim clinical trials, transplantation of bone
marrow stem cell derivatives, primarily MSCs and MNCs, is deemed
safe for stroke, but their efﬁcacy remains elusive. Conclusive interpretations of the clinical data are hindered by small number of
enrolled patients and the open-labeled approach in some of these
trials. Moreover, vis-a-vis comparisons between these trials will be
difﬁcult because of different donor cells and varied clinical transplant protocols (Table 1). Phenotypic markers for MSCs include SH2 and SH-4 [45]; speciﬁc ﬂow cytometric antibodies (CD3, CD14,
CD16, CD19, CD20, CD34, CD45, CD56, Lin 1, CD133-2) [46]; or limited to CD34 and CD45 [47]; or magnetic cell isolation procedures
focused on CD34+ cells [48]; MAPCs are deﬁned as c-Kit+, CD9+,
CD13+, CD31+, CD44−, MHC-I-, CD45−, Thy1- [49, 53], while SB623
are Notched-induced MSCs [15, 50, 51, 54, 55]. Additionally, the
therapeutic windows spanned from acute to chronic stroke stages,
as well as routes of administration varied across trials [45–51].
A major contributor to the failure of clinical trials to reach
efﬁcacy endpoints is the translational discrepancy between the
laboratory and clinical stem cell transplant protocols (Table 1).
Efﬁcacy readouts in the laboratory, which were achieved under
strict cell dose and timing of transplantation windows, are not
strictly followed in the clinic. The preclinical effective intravenous dose is around 4 million cells in a stroke rat weighing
250 g, which translates to approximately 840 million cells in a
stroke patient weighing 75 kg [56], yet most clinical trials use
doses well below this efﬁcacious dose [45, 47, 48]. Of note,
stroke patients who received a dose that adhered to this preclinical cell dose displayed clinical improvements [46]. In the
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Reneuron, Bridgend, UK) [16], and even with the present modiﬁcation of induced pluripotent stem cells (iPSCs) for stroke
indication, still maintain the need to generate an ample
amount of neuron-like cells based on the notion that functional recovery can be achieved by repairing the neuronal synaptic circuitry via replenishing infarcted cells and ischemic
cells with neuronal cells. The recognition that stroke not only
affects neurons but also other neural cell types, especially vascular cells, prompted the search for alternative regenerative
processes that rescue in tandem neural and vascular cells,
under the theme of attenuating the impaired neurovascular
unit [17]. Toward stimulating these non-neuronal repair processes,
the stem cells’ by-stander effects have been proposed, including
the grafted cells’ ability to secrete substances that promote neurogenesis, angiogenesis, vasculogenesis, anti-inﬂammation, among
other therapeutic substances. Over the last 5 years, additional
novel stem cell component-based mechanisms have been demonstrated to accompany stem cell therapy, such as the transfer
of stem cell-derived mitochondria, exosomes, microvesicles, and
micro-RNAs into the ischemic area [18–22]. Additionally,
although stroke is traditionally considered a brain disorder, the
role of peripheral organs, such as the spleen and the gut, has
been implicated in the disease pathology, and that sequestration
of their aberrant inﬂammatory and microbiome response has
been deemed therapeutic, which can be achieved with stem cell
transplantation [19, 23]. With these regenerative mechanisms
ascribed to stem cells, developing them into stem cell release
criteria would enhance the quality control screening of viable and
transplantable cells that would ensure therapeutic potency following their transplantation into the stroke brain. One could also envision using these potency assays as indices of stem cell functional
status during the poststroke transplantation period, in that one
can monitor the levels of growth factors, inﬂammation, mitochondrial function, splenic function, and gut microbiota both
centrally and peripherally. Thus, in addition to phenotypic
markers of stemness and the optimal transplant regimen
(i.e., dose, timing, and route of delivery), adding these potency
assays will likely improve the clinical outcomes of stem cell
therapy for stroke.
These important basic science experiments have laid the
groundwork for advancing cell therapy for stroke to the clinic. Recognizing that same species allogeneic transplantation (i.e., from
rat-to-rat cell-donor-transplant recipient to human-to-human
cell-donor-transplant recipient) may provide safe and effective
treatment for the envisioned clinical trial, the search for transplantable human cells became paramount to realize translation
of cell therapy from the laboratory to the clinic. The use of fetal
cells poses ethical and logistical challenges. A moratorium in the
1990s on the use of federal funds for embryonic stem cell
research, and with iPSCs still not yet available at that time, nulliﬁed pursuing these tissue sources for clinical cell therapy. The
ﬁrst human clinical trial using human neuroteratocarcinoma cells
transformed into postmitotic neurons transplanted into stroke
patients was performed in 1998 [24] based on our earlier preclinical work [13]. Financial strain to the company sponsor of these
neuroteratocarcinoma cells contributed to abandoning this clinical trial, prompting the search for alternative transplantable cells.
Adult tissue-derived stem cells, including those harvested from
bone marrow, umbilical cord, and adipose, eventually took center stage and to date remain as the front-runner cell source for
cell therapy for stroke [25–27].

Translating Stem Cells for Stroke Clinical Trials
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Table 1. Stem cell transplantation protocols for stroke therapy
Reports

Stem
cell type Route

Dose

Timing

Laboratory studies
MAPCs

i.c.

0.4 million

7 days

Mays et al. [59]

MAPCs

i.v.

4 million

1–7 days

Acosta et al. [89]

MSCs

i.v.

4 million

60 days

Borlongan et al. [90] MSCs

i.c.

0.2 million

3 hours

i.v.

100 million

4 weeks

Clinical trials
Bang et al. [45]

MSCs

Savitz et al. [46]

MNCs

i.v.

100 million

1–3 days

Prasad et al. [47]

MNCs

i.v.

280.75 million

18.5 days

Banerjee et al. [48]

HSCs

i.a.

100 million

7 days

Hess et al. [49]

MAPC

i.v. 400–1,200 million 24–48 hours

Steinberg et al. [50]

SB623

i.c.

2.5–10 million

Hess et al. [60]

MAPC

i.v.

1,200 million

18–36 hours

Kalladka et al. [91]

CTX-DP

i.c.

2–20 million

6–60 months

MSCs

i.v.

50 million

4 weeks

Lee et al. [92]

6–60 months

Type of cells, route of administration, doses, and timing are listed.
Abbreviations: HSCs, hematopoietic stem cells; i.c., intracerebral;
MAPCs, multipotent adult progenitor cells; MNCs, mononuclear cells;
MSCs, mesenchymal stem cells.

same token, the intracerebral dose of 200,000 cells is efﬁcacious
in the stroke rat, which is equivalent to approximately 56 million
cells in the stroke patient, but again the clinical doses (2.5 and
5 million cells) used were at least 10-fold below this dose, which
may explain the lack of efﬁcacy [50, 51]. The cell dose found
effective in the stroke rat was correctly gated in the MAPC trial
(400 to 1,200 million cells) [49] but still did not reach efﬁcacy
[57]. Post hoc analysis, however, revealed that those patients
who received the MAPC transplants less than 36 hours exhibited
functional improvements [58], which were predicted in the preclinical study [59] and now the targeted therapeutic window in a
subsequent MAPC trial [60]. Strict adherence to the preclinical
outcomes of optimal cell dose, timing, and route is a must if efﬁcacy is to be achieved in the clinic.
Lab-to-clinic translation and the subsequent clinical trial
design of stem cell therapy have emphasized the logistics and
technical aspects of the transplant regimen and may have
neglected the basic science discoveries that deﬁned stemness
properties and mechanisms of stem cells. The rule of thumb when
contemplating any envisioned stem cell clinical product must consider a well-deﬁned set of phenotypic markers of the stem cells
and a solid insight into their mode of action. Access to clinicalgrade stem cells should preclude a set of product release criteria
of either homogenous population of cells or a consistent and
reproducible generation of the same stem cell population. The
clinical transplant regimen should also build upon the lessons
learned from the laboratory about postulated mechanisms, including cell replacement, growth factor secretion, and promotion of
endogenous brain repair processes [61–65], which may synergistically work together to combat the multipronged cell death pathways associated with stroke [66–68]. In view of this intricate strokeinduced cell death cascade, stem cell therapy may be optimized
not as a stand-alone treatment but as a combination therapy with
tissue Plasminogen Activator (tPA), other neuroprotective drugs,
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biomaterials [69], or thrombectomy (see below), as well as with
standard stroke care management involving rehabilitation [70, 71].
Although efﬁcacy in preclinical stroke models is paramount
toward moving the stem cell product to the clinic, equally important is establishing the safety proﬁle of the stem cells, such as
their proliferative, tumorgeneic or ectopic tissue formation capacity, persistence speciﬁcally tissue or organ deposition, and cell fate
following transplantation into the stroke brain. The differentiation
of stem cells into a phenotype when lodged in a particular organ
may elicit deleterious immune response or inﬂammatory reaction
that can be toxic or can elicit tumorigenesis. Ample consideration
should also be given when using genetically engineered stem
cells, such as SB623 or immortalized cells such as CTX03 [26, 30].
With the notion that stem cells may confer therapeutic effects via
secreted substances, there is also a translational push favoring decellularized over cellularized compositions, and such pharmacologiclike or cell-free treatments may beneﬁt from the translational Stroke
Treatment Academic Industry Roundtable (STAIR) criteria toward
achieving the neuroprotective drug’s safety proﬁle [72]. Speciﬁc
safety deliberations are necessary when using freshly harvested, cultured, or cryopreserved cells, naked, encapsulated, or extracellular
matrix-loaded cells, and novel delivery devices such as sustained,
controlled, and highly regulated nanoparticles, exosomes, extracellular vesicles, microRNAs, mitochondria, and other cellular
components [18, 20, 73–76]. The once cell-directed transplantation approach has been replaced with much sophisticated cell
components that have expanded toward emerging therapies
using innovative cell-derivative and even cell-free compositions
that will require a unique set of safety outcome evaluations.
If clinical entry of stem cell products is the desired goal, then
the use of clinical-grade stem cells from the get-go would allow a
more efﬁcient entry of stem cells to the clinic. The rigid regulatory translational path of stem cell from the laboratory to the
clinic provides no allowance for modiﬁcation of the stem cell
product. Developing clinical-grade lines would require many
changes to the original protocols, because the standards for
manufacturing clinical biological agents are stricter than the standards for research-grade cell lines, necessitating the need to ﬁnd
alternatives to the laboratory animal-derived reagents that most
likely are not allowed for clinical use [77]. In the end, the Good
Manufacturing Practice (GMP)-manufactured stem cells are likely
different from the laboratory-grade stem cells, in that the phenotype and biological properties originally designed to treat a speciﬁc disease in the laboratory may now have a different disease
indication in the clinic. Similarly, other cell manufacturing technical aspects may change the eventual stem cell product. Key cell
product release criteria to the commercial and clinical application
of stem cells are suitable cryopreservation protocols for longterm storage, which may prove refractory for some stem cells
[78]. The expansion time and ampliﬁcation process, including the
matrices and reagents (e.g., serum or platelet lysate) under clinical GMP may generate MSCs that differ in their immunomodulatory properties [79], thereby affecting the cells’ therapeutic
effects. Finally, because human stem cells are tested in animal
models, this cross-species paradigm likely will present with different safety and efﬁcacy scenario in the same-species clinical
application. This would indicate that the risk proﬁle of stem
cell-based products should consider the envisioned clinical
product of autologous or allogeneic stem cells, including their
differentiation status and proliferation capacity, the route of
administration, the intended location, and long-term survival
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of engrafted cells which will affect the clinical risks of tumor
formation, unwanted immune responses, and the transmission of
adventitious agents [80], and the clinical efﬁcacy readouts. In the
end, the theoretical or potential application of stem cells observed
in animal studies should closely approximate the applied setting in
the clinic if GMP-certiﬁed stem cells were to replicate the safety
and efﬁcacy proﬁle of the lab-grade stem cells.
To this end, in support of allowing the basic science-generated
efﬁcacy and safety readouts of stem cell transplantation in preclinical stroke to dictate the entry of this therapy to the clinic, a
set of guidelines for translational research and clinical trial design
has been recommended by a consortium of basic scientists, clinicians, industry partners, and NIH and Food and Drug Administration regulators under the consortium of Stem cell Therapeutics as
an Emerging Paradigm for Stroke (STEPS). A collaborative effort
among these stakeholders may provide an expeditious clinical
entry of stem cell therapeutics. The overarching thesis of STEPS is
that basic science should dictate the translation and eventual clinical application of stem cell therapy for stroke. Unfortunately, a
careful examination of the literature reveals few studies adhering
to these STEPS lab-to-clinic translational guidelines [81]. The
investigation of stem cell therapy in a clinically relevant setting,
in particular assessing its efﬁcacy and safety in direct comparison
to rehabilitation, has not been fully examined [81].
In an effort to enhance successful translation of stroke therapeutics, a new NIH NINDS initiative called Stroke Preclinical Assessment Network (SPAN) program [82] has solicited projects designed
to evaluate the potential of neuroprotective drugs in improving
functional outcomes of currently approved stroke treatments, speciﬁcally thrombectomy. Approximately 87% of strokes are ischemic
in nature and occur due to an arterial occlusion [83]. The most
common approach to endovascular revascularization of large vessel occlusion (LVO) is stent retriever thrombectomy [84]. Once a
stent is deployed at the occlusion site, the clot becomes engaged
and entrapped within the struts of the device, allowing subsequent withdrawal of both the stent and clot as a single unit. Stent
retriever thrombectomy is currently recommended in patients
with acute ischemic stroke from LVO [85]. However, the risk of
excessive bleeding is inherent with thrombectomy, necessitating
the need for adjunctive treatments to minimize such adverse
effect. The NIH SPAN program acknowledges the transient middle
cerebral artery occlusion (tMCAO) as the standardized and

validated model of stroke. By subsequently adding aging and other
comorbidities to this tMCAO model and by enlisting multiple
established laboratories (with solid track record of publications on
the use of this MCAO model), a much more stringent platform will
be in place to test therapeutics for translation into clinical application. The anticipated six SPAN sites will be identiﬁed and tasked to
work closely together under the guidance of a coordinating center
consisting of key thought leaders in stroke and neuroprotection,
epitomizing the collaborative spirit of STEPS and STAIR consortia.
Not too long ago, big pharmaceutical companies have remained
on the sidelines from supporting stroke therapeutics, primarily
due to the bleak outlook that the disease is treatable with neuroprotective drugs beyond thrombolytic agent tPA or mechanical
thrombectomy. Now we have reached the crossroad of identifying
a neuroprotective drug, not as a stand-alone but as an adjunct to
thrombectomy. One can envision stem cells as biologics [86] operating as pharmacologic-like agents as noted above, which may similarly be combined with thrombectomy. As noted above, stem cells
may secrete a cocktail of therapeutic growth factors that collectively can induce regenerative processes [87, 88] which may aid
the neurovascular unit to respond better to thrombectomy.
So are we there yet? The recent failures of stem cell transplantation to reach efﬁcacy in stroke clinical trials (MAPC and
SB623) appear to set the bar much higher before we can
replace the current designation of “experimental treatment”
to “treatment option” for stem cell therapy (Figure 1). At the
very least, a redesign of ongoing trials is needed to reconcile
the disconnect between the laboratory and the clinical stem
cell transplant protocols. A much narrower treatment window
(i.e., transplantation within 36 hours of stroke onset) has now
been indicated for the second MAPC clinical trial in acute
ischemic stroke patients [60]. A cell dosage closer to the preclinical dose-approximated 56 million cells will likely need to
be pursued with a new SB623 clinical trial for chronic stroke
patients. Unfortunately, the long wait is not yet over. A collaborative effort and a commitment to basic science represent
critical lab-to-clinic translational enabling factors toward a safe
and effective stem cell therapy for stroke.
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Figure 1. Lab-to-clinic translational hurdles in stem cell therapy for stroke. Several factors enable the ascent of stem cell therapy at the
basic science, translational, and clinical levels. Tissue sources for stem cell transplantation include fetal cells, iPSCs, ESCs, and adult tissuederived cells such as bone marrow MSCs. At the basic science level, stemness and underlying mechanisms of stem cells need to be probed. At the translational level, the transplant regimen needs to be optimized. At the clinical level, the safety and efﬁcacy of the
transplanted cells must be ensured, with the efﬁcacy readouts remaining elusive in recent clinical trials. Abbreviations: ESCs, embryonic
stem cells; iPSCs, induced pluripotent stem cells; MSCs, mesenchymal stem cells.
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